Lunsumio subkutan 5 mg/0.5ml
Lunsumio subkutan 5 mg/0.5ml is a medicine authorised by Swissmedic under authorisation number 70221. The authorisation holder is Roche Pharma (Schweiz) AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 03 July 2026 and the authorisation is limited until 09 February 2027. ATC code L01FX25 places the medicine in the group Antineoplastic agents.
| Authorisation number | 70221 |
|---|---|
| Name | Lunsumio subkutan 5 mg/0.5ml |
| Full name | Lunsumio subkutan 5 mg/0.5ml, Injektionslösung |
| Authorisation holder | Roche Pharma (Schweiz) AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01FX25 |
| First authorisation | 03 July 2026 |
| Authorisation validity | 09 February 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Lunsumio subkutan 5 mg/0.5ml, Injektionslösung | A | 03 July 2026 |
| 2 | Lunsumio subkutan 45 mg/1ml, Injektionslösung | A | 03 July 2026 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Durchstechflasche(n) | L01FX25 | 07.16.1. | A |
| 2 | 1 | Durchstechflasche(n) | L01FX25 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Lunsumio subkutan 5 mg/0.5ml authorised in Switzerland?
Yes. Lunsumio subkutan 5 mg/0.5ml is authorised by Swissmedic under authorisation number 70221, data as of 01 September 2026. The authorisation is limited until 09 February 2027.
Which dispensing category does Lunsumio subkutan 5 mg/0.5ml have?
Lunsumio subkutan 5 mg/0.5ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Lunsumio subkutan 5 mg/0.5ml?
The authorisation holder is Roche Pharma (Schweiz) AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.